Matching Geography

Reports matching your search in:
 
 

Research Assistance

 

Free Alert Me service

Receive bi-weekly email alerts on new market research

Sign Up Today!
 

Asthma

1594

Asthma is a disease characterized by recurrent attacks of breathlessness and wheezing, which vary in severity and frequency from person to person. This condition is caused by the inflammation of the air passages in the lungs. It affects the sensitivity of the nerve endings in the airways so that they become easily irritated. In an attack, the lining of the passages swells, causing the airways to narrow and reducing the flow of air in and out of the lungs.
Although asthma is a chronic obstructive condition, it is not considered a part of COPD as this refers specifically to combinations of bronchiectasis, chronic bronchitis, and emphysema. Unlike these diseases, the airway obstruction in asthma is usually reversible. However, if left untreated, asthma can result in chronic inflammation of the lungs and irreversible obstruction. In contrast to emphysema, asthma affects the bronchi, not the alveoli. Public attention in the developed world has increased recently because of its rapidly increasing prevalence, affecting up to a quarter of urban children.

The strongest risk factors for developing asthma are a person’s exposure to allergens and a family history of asthma or allergy. Exposure to tobacco smoke and exposure to chemical irritants in the workplace are additional risk factors. Workplace conditions, such as exposure to fumes, gases or dust, are responsible for 11% of asthma cases worldwide.

RSS Feeds

All reports in Asthma

< prev 1  2  3  4  next >
Asthma – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. 'Asthma - Pipeline Review, H1 2012' is built using data and information ...  |  more...
$500.00
Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H1 2012
2/27/2012 | published by: Global Markets Direct
... pipeline. This report provides information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the ...  |  more...
$500.00
Asthma Global Clinical Trials Review, H2, 2011
12/31/2011 | published by: GlobalData
... to the clinical trials on Asthma . It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage ...  |  more...
$1,000.00
Clinical Trial Recruitment in Respiratory Diseases - Most Clinical Trial Activity Focused on Asthma and COPD
11/22/2011 | published by: GBI Research
... COPD”, provides an in-depth analysis of patient recruitment scenario for major indications under respiratory diseases. The report analyzes the number of clinical trials conducted for major indications. The report provides information about the total number ...  |  more...
$3,500.00
Telemonitoring: Challenges & Opportunities
11/17/2011 | published by: Espicom Healthcare Intelligence
... provision. Patient monitoring, observation and diagnosis, no longer rooted in the consulting room, provides 24- hour surveillance and timely clinical interventions when conditions deteriorate. And telemonitoring products are delivering these services across a range of ...  |  more...
$1,740.00
Industry Outlook: Trends in Respiratory Disease Strategies
11/1/2011 | published by: Decision Resources
... on the cardiac safety of metabolic agents. Emerging therapies such as Orexigen/Takeda's Contrave, Abbott's Meridia, and GlaxoSmithKline's Avandia all have recently faced intense regulatory scrutiny over their cardiovascular safety profiles. Although drug development guidelines for ...  |  more...
$4,600.00
China Asthmatic Prescription Drugs Sales Data 2006-2010
11/1/2011 | published by: Draco Healthcare Consulting LLC
... and drug purchasing data from extensive hospital coverage in 16 major cities and more than 300 hospitals. Sampled hospitals are from major Chinese cities across different geographic locations, including Beijing, Shanghai, Guangzhou, Nanjing, Chengdu, Chongqing, ...  |  more...
$8,000.00
Conference Documentation: COPD: Novel Therapeutics and Management Strategies
10/20/2011 | published by: SMI Publishing, Ltd
... well as highly respected academic and medical figures, this is your opportunity to enjoy presentations on the latest hot topics surrounding COPD and to network with key industry professionals. This conference continues to promote increased ...  |  more...
$800.00
Special Report: The Pricing and Reimbursement Environment for Respiratory Disease Therapies
10/1/2011 | published by: Decision Resources
... front and center as the subjects of efforts to improve patient outcomes while containing costs to health systems. Governments and other payers are compelled to invest substantial resources in the management of these disorders. At ...  |  more...
$4,600.00
Asthma - Pipeline Review, H2 2011
9/28/2011 | published by: Global Markets Direct
... with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Asthma. 'Asthma - Pipeline Review, H2 2011' is built using data and information ...  |  more...
$500.00
Epidemiology: Asthma
9/22/2011 | published by: Datamonitor
... that there were 63.7 million total asthma cases in all ages in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) in 2010, forecasted to rise to 65.7 million total ...  |  more...
$5,700.00
Epidemiology: Asthma
9/22/2011 | published by: Datamonitor
... million total cases by 2020. Due to stable prevalence rates of asthma, population changes are responsible for the small change in the number of cases during this time.Gain insight into market potential, including a robust ...  |  more...
$5,700.00
Novel Drug Targets and Strategies for Asthma and Chronic Obstructive Pulmonary Disease
9/1/2011 | published by: Decision Resources
... Patients with severe corticosteroid-refractory asthma are desperate for novel treatment options, a need that creates opportunities for development of innovative therapies that target novel mechanisms of action. Opportunities are also available for COPD drugs that ...  |  more...
$4,600.00
Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries
9/1/2011 | published by: GBI Research
... “Respiratory Disorders Therapeutics Market to 2017 - Novel Pipeline Molecules such as VX-770 and pirfenidone May Offset Negative Effect of Patent Expiries”, which provides insights into the global respiratory disorders market and market forecast until ...  |  more...
$3,500.00
Special Report: The Respiratory Disease Pipeline—A Competitive Review
9/1/2011 | published by: Decision Resources
... analysis of these and other unmet needs in the respiratory disease therapeutic area, we have confirmed 117 respiratory agents in active clinical development. In this report, we examine the respiratory disease pipeline, the companies involved ...  |  more...
$9,200.00
Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
8/31/2011 | published by: GlobalData
... Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics market. The report identifies the key trends shaping and driving the global ...  |  more...
$3,500.00
Asthma Therapeutics - Pipeline Assessment and Market Forecasts to 2018
8/31/2011 | published by: GlobalData
... essential source of information and analysis on the global Asthma Therapeutics market. The report identifies the key trends shaping and driving the global Asthma Therapeutics market. The report also provides insights on the prevalent competitive ...  |  more...
$3,500.00
Epidemiology: COPD - Aging population and stable smoking rates to raise case numbers
8/17/2011 | published by: Datamonitor
... Italy, Spain, and the UK). Approximately 54% of cases were mild, 38% were moderate, and 8% were severe or very severe. Features and benefits Gain insight into market potential, including a robust 10-year epidemiology forecast ...  |  more...
$5,700.00
Asthma and COPD Therapies: World Market 2011-2021
8/8/2011 | published by: Visiongain
... total world, company, product and national levels. Through our research and analysis we aim to save you time and help in your decisions. How will competition affect the asthma and COPD treatment market? We show ...  |  more...
$2,331.00
Acute Respiratory Distress Syndrome (ARDS) Therapeutics - Pipeline Assessment and Market Forecasts to 2017
7/1/2011 | published by: GlobalData
... Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Acute Respiratory Distress Syndrome Therapeutics market. The report identifies the key trends shaping and driving the global Acute ...  |  more...
$2,000.00
Asthma - Executive Market Summary 2011
6/3/2011 | published by: Timely Data Resources, Inc.
... and treatment cost information is provided for various treatment types. General information on the asthma market, as well as sales of leading drugs and therapies are provided. Please note, this file is delivered as a ...  |  more...
$995.00
Chronic Obstructive Pulmonary Disease (COPD) - Executive Market Summary 2011
6/3/2011 | published by: Timely Data Resources, Inc.
... overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the COPD market, as well as sales of leading drugs and therapies are provided. Please note, this file ...  |  more...
$995.00
The Asthma, COPD & Allergic Rhinitis Market Outlook to 2016
5/27/2011 | published by: Business Insights
... brands within each indication, enabling the reader to identify growth of the leading brands, key drug classes and leading players through 2016. Features and benefits Quantify patient potential and assess treatment trends and sales patterns ...  |  more...
$3,835.00
Respiratory Therapeutics and Devices Markets
5/1/2011 | published by: TriMark Publications
... and it is expected to be growing vigorously into the future. This TriMark Publications report analyzes various respiratory therapeutics and devices markets, with special attention paid to therapeutic remedies for chronic obstructive pulmonary disease (COPD), ...  |  more...
$3,400.00
Vulvar Cancer - Pipeline Review, Q2 2011
4/30/2011 | published by: Global Markets Direct
... for Vulvar Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Vulvar Cancer. 'Vulvar Cancer - Pipeline Review, Q2 2011' ...  |  more...
$500.00
< prev 1  2  3  4  next >